Hims & Hers Health, Inc. (NYSE:HIMS) Stock Holdings Trimmed by Foresite Capital Management V LLC

Foresite Capital Management V LLC lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 46.6% during the fourth quarter, Holdings Channel reports. The firm owned 939,860 shares of the company’s stock after selling 819,454 shares during the period. Hims & Hers Health makes up about 18.9% of Foresite Capital Management V LLC’s holdings, making the stock its 2nd biggest holding. Foresite Capital Management V LLC’s holdings in Hims & Hers Health were worth $22,726,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Crewe Advisors LLC acquired a new position in Hims & Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC increased its position in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth approximately $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Trading Up 1.2 %

Hims & Hers Health stock opened at $52.04 on Friday. Hims & Hers Health, Inc. has a 52 week low of $12.07 and a 52 week high of $72.98. The stock has a market cap of $11.56 billion, a P/E ratio of 118.28 and a beta of 1.84. The stock has a 50 day moving average of $32.97 and a 200-day moving average of $32.35.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue was up 110.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.05 EPS. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. UBS Group reiterated a “mixed” rating on shares of Hims & Hers Health in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday. Truist Financial cut their price objective on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Bank of America upped their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research report on Tuesday, April 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $61.00 target price on shares of Hims & Hers Health in a report on Tuesday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average target price of $37.67.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 50,000 shares of the stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $36.39, for a total transaction of $1,819,500.00. Following the sale, the chief executive officer now directly owns 92,103 shares of the company’s stock, valued at approximately $3,351,628.17. This represents a 35.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares in the company, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 650,500 shares of company stock worth $25,790,311. Corporate insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.